Evaxion A/S - Sponsored ADR EVAX

Healthcare — Biotechnology

Cash Flow Champion (3y)

Growth Flags show if company had growth for consecutive years

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
P/E ratio	0.00	0.00	0.00	—	—	—	—	—	—
P/S ratio	2.84	0.00	0.00	—	—	—	—	—	—
P/FCF ratio	0.00	0.00	0.00	—	—	—	—	—	—
P/Operating CF	(3.93)	(0.52)	(8.94)	—	—	—	—	—	—
P/B ratio	1.78	0.00	0.00	—	—	—	—	—	—
Price to Tangible BV	1.79	0.00	0.00	—	—	—	—	—	—
EV/Sales	1.33	0.00	0.00	—	—	—	—	—	—
EV/EBITDA	0.00	0.00	0.00	—	—	—	—	—	—
EV/Operating CF	(0.43)	(0.25)	(3.68)	—	—	—	—	—	—
EV/FCF	(0.42)	(0.25)	(3.61)	—	—	—	—	—	—
Quick Ratio	5.66	1.72	0.90	3.77	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Current Ratio	5.85	2.01	1.18	4.51	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Net Debt/EBITDA	1.87	(0.27)	(0.23)	0.13	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Debt/Assets	25.15%	78.39%	81.81%	45.19%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡
Debt/Equity	0.42	(5.92)	(2.23)	1.20	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Asset Turnover	0.37	0.26	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Operating CF/Net income	0.86	1.22	0.80	1.11	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Capex/Depreciation	(0.02)	0.00	(0.14)	(0.51)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	—
Depreciation/Fixed assets	0.19	0.17	0.14	0.12	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Interest Coverage	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
ROE	(100.18%)	331.20%	(1,238.11%)	(113.74%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
ROA	(37.69%)	(83.29%)	(126.74%)	(74.51%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
ROIC	(608.14%)	(421.78%)	(5,979.80%)	(311.38%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	—
Cash ROIC	(20.98%)	(116.80%)	(193.31%)	(96.85%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Return on Tangible Assets	(32.16%)	(133.57%)	(394.46%)	(129.45%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Accounts Receivable Turnover	6.26	2.84	0.08	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Accounts Payable Turnover	0.00	0.00	0.00	0.23	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Inventory Turnover	—	—	—	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Average Days of Receivables	41.99	168.09	4,075.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Average Days of Payables	0.00	0.00	0.00	1,332.09	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Days of Inventory on Hand	—	—	—	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Research and Development Expense of Revenue	132.51%	312.71%	16,323.29%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Selling, General and Administrative Expense of Revenue	90.16%	227.84%	14,183.56%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Intangible Assets out of Total Assets	0.00	0.00	0.00	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡
Share Based Compensation of Revenue	4.08%	10.68%	656.16%	0.00%	‡‡‡	‡‡‡	‡‡‡	—	—
Graham Net Nets	0.45	(1.75)	(0.09)	—	—	—	—	—	—
Graham Number	0.00	0.00	0.00	—	—	—	—	—	—
Earnings Yield	(10.90%)	(67.85%)	(35.97%)	—	—	—	—	—	—
Free Cash Flow Yield	(111.12%)	(731.15%)	(29.03%)	—	—	—	—	—	—
Revenue per Share	1.17	3.12	0.13	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Operating CF per Share	(1.03)	(12.06)	(32.36)	(54.51)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Capex per Share	0.00	0.00	(0.16)	(0.62)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	—
Free Cash Flow per Share	(1.04)	(12.06)	(32.52)	(55.13)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Cash per Share	3.63	5.55	10.21	27.88	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Shareholders Equity per Share	2.66	(1.54)	(8.65)	17.56	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Interest Debt per Share	0.00	0.00	0.00	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Book value per Share	2.66	(1.54)	(8.65)	17.56	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Free Cash Flow	(6.64)	(12.94)	(17.78)	(26.07)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Working Capital	20.64	4.40	1.27	13.22	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Capital Expenditures	(0.01)	—	(0.09)	(0.29)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Net Current Asset Value	13.53	(5.37)	(9.27)	3.26	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Average Receivables	1.20	1.18	0.91	1.21	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Average Payables	2.58	2.83	2.39	2.47	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Average Assets	20.45	12.69	17.46	31.09	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
Average Common Equity	7.69	(3.19)	1.79	20.37	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—
EV/EBIT	0.00	0.00	0.00	—	—	—	—	—	—
Capex to Sales	0.00	0.00	1.19	0.00	‡‡‡	‡‡‡	‡‡‡	—	—
Net Profit Margin	(102.38%)	(316.00%)	(30,308.22%)	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—
Price to Operating Income	0.00	0.00	0.00	—	—	—	—	—	—

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now